TAGAMET HB (cimetidine) by Teva is histamine h2 receptor antagonists [moa]. First approved in 1995.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
TAGAMET HB (cimetidine) is an oral histamine H2-receptor antagonist that reduces gastric acid production and treats heartburn, acid indigestion, and peptic ulcer disease. It works by blocking histamine-induced acid secretion in the stomach, providing symptomatic relief for acid-related gastrointestinal conditions.
As LOE approaches, the commercial team is likely focused on defending market share against generic competition and optimizing profitability on a declining revenue base.
Histamine H2 Receptor Antagonists
Histamine-2 Receptor Antagonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Effect of Cimetidine on the PK of Imeglimin
Effect of Cimetidine on the Pharmacokinetics of Lucerastat in Healthy Subjects
Drug-drug Interaction Study of CHF5993 With Cimetidine
Evaluating The Effects Of Cimetidine On The Elimination Of PD 0332334 From The Body
Effect of Cimetidine on the Single-Dose PK of IV- Administered MNTX
Worked on TAGAMET HB at Teva? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on TAGAMET HB offers limited career growth due to its mature, generic-competed lifecycle and minimal linked job openings (0 positions). Professionals on this product typically focus on cost management, regulatory compliance, and defending shelf space rather than launching or growing a franchise.